

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:550

09/381,747

List of Patents and Publications for Applicant's

Applicants

Mar Tormo et al.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

09/22/99

Group:

~~Unknown~~

1635

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
KAL	B1	WO93/20200	10/14/93	GB			
KAL	B2	WO95/08350	03/30/95	US			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
KAL	C1	M.T. Almazan et al., "Methylphosphonate-containing oligonucleotides efficiently and specifically inhibit Bcl-2 and erbB-2 expression in vitro," <i>Proc. Amer. Assoc. Cancer Res.</i> , 37:353, Abstract No. 2407, March 1996
KAL	C2	M. Tormo et al., "Antitumor activity of liposomal-bcl-2-antisense oligonucleotides in follicular lymphoma," <i>Proc. Amer. Assoc. Cancer Res.</i> , 37:173, Abstract No. 1190, March 1996
KAL	C3	Fred D. Ledley, "Non-viral gene therapy," <i>Current Opinion in Biotechnology</i> , 5:626-636, 1994
KAL	C4	Yongyut Rojanasakul, "Antisense oligonucleotide therapeutics: drug delivery and targeting," <i>Adv. Drug Delivery Reviews</i> , 18:115-131, 1996

EXAMINER:

Kale E. Zaconien

DATE CONSIDERED:

06-29-00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)